DRKS00040963招募中不适用
Development of a novel method for the first-time determination of the patient-specific implant placement timing following augmentation – a retrospective study.
Universitätsmedizin der Goethe-Universität Frankfurt am Main, Klinik für Mund-, Kiefer- und Plastische Gesichtschirurgie0 个研究点目标入组 10 人开始时间: 2026年4月13日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 —（—）
- 性别
- All
入选标准
- •Tooth extraction with socket/ridge preservation using bone graft material performed
- •Post-extraction and pre-implantation CBCT scan available
- •Histological specimens/biopsies from the augmentation site available
- •Treatment performed within the period 01/2020–12/2025
排除标准
- •Regeneration period between extraction and implantation >6 months
研究者
相似试验
进行中（未招募）
不适用
Development and feasibility evaluation of a mixed reality intervention for selective and sustained attention in adolescent basketball playersSelective and sustained attention in healthy adolescent basketball players.DRKS00040875Riga Stradinš University14
进行中（未招募）
不适用
Study to check the safety and efficacy of cosmetic productCTRI/2026/07/113999Bajaj Consumer Care Ltd30
尚未招募
不适用
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on
Background Insulin (Eluminate-3)Type 2 Diabetes MellitusjRCT203126026280
招募中
不适用
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)Type 2 Diabetes MellitusjRCT2031260261165
招募中
不适用
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)Type 2 Diabetes Mellitus and Impaired Renal FunctionjRCT2031260268118